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Abstract
Background: Cholesterol oxides, the oxygenated derivatives of cholesterol, have been shown to
cause programmed cell death in a variety of cell types. Using N9 microglia, this study was designed
to investigate the molecular events induced by cholesterol oxides prior to the execution of
programmed cell death.
Results: Microglia were very sensitive to 25-OH-cholesterol, such that a 2-day treatment of the
cells with 5 µM 25-OH-cholesterol reduced cell viability to 5–10% of controls. There was a dose-
and time-dependent increase in c-jun and phospho-c-jun levels in microglia prior to this 25-OH-
cholesterol induced cell death. In contrast, 7-β -OH-cholesterol, which was relatively non-toxic to
microglia, did not increase phospho-c-jun levels. Peroxisome proliferator-activated receptors
(PPARs) are a group of nuclear receptors that have important roles in atherogenesis. Results from
this study indicate that PPAR agonists such as 15d-PGJ2, indomethacin and WY14643 can attenuate
cholesterol oxide induced c-jun activation and cell death in microglia.
Conclusions:  Peroxisome proliferator-activated receptor agonists may be useful in future
development of pharmacological agents against cholesterol oxide induced cytotoxicity.
Background
High levels of serum cholesterol and low density lipopro-
tein (LDL) have been associated with the genesis of
atherosclerosis, a leading cause of cardiovascular diseas-
es that affect a large number of people all over the world.
It has become clear that the pathological conditions as-
sociated with an excess level of LDL are actually caused
by the oxidized products of LDL [1]. More specifically,
cholesterol oxides (also termed oxysterols), the oxygen-
ated derivatives of cholesterol, appear to be the major cy-
totoxic components in oxidized LDL [2,3]. These
compounds have a hydroxyl- or a keto- group on the cho-
lesterol molecule. Examples of cholesterol oxides in-
clude: 7-OH-, 7-keto-, 19-OH-, 22-OH- and 25-OH-
cholesterol (see [4] for a recent review).
Tissue damage caused by cholesterol oxides has been the
subject of many studies. Cholesterol oxides are cytotoxic
to a variety of cell types [5]. These compounds can dam-
age endothelial cells, smooth muscle cells and fibrob-
lasts, all of which are major components of the arterial
wall. Cholesterol oxides are also toxic to cells derived
from the immune system, such as macrophages, thymo-
cytes, lymphoma cells and leukemic T-cells. Pharmaco-
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logical agents capable of reducing cholesterol oxide
toxicity are yet to be discovered.
The mode of cell death caused by cholesterol oxides has
generated much interest recently. There is evidence
showing that programmed cell death (PCD, also known
as apoptosis) occurs in some cells treated with cholester-
ol oxides [6–8]. PCD is a special type of cell death that
can be induced by growth factor deprivation or toxins
[9–11]. By using the PCD induced by nerve growth factor
deprivation in sympathetic neurons as an example, the
cell death process begins with the generation of reactive
oxygen species followed by a significant decrease in glu-
cose uptake, RNA and protein synthesis, activation of the
immediate early protein, c-jun, and release of cyto-
chrome c from mitochondria. Cell death is executed by
the activation of a family of proteases termed caspases.
Morphologically, cells dying of PCD appear atrophic and
exhibit condensed nuclei, which can be stained with nu-
clear stains (bisbenzimide or propidium iodide), or by
the TUNEL assay. DNA extracted from cells dying of
PCD is often fragmented and shows a characteristic lad-
der-type pattern on the agarose gel upon electrophoresis.
MAP kinases (Mitogen-Activated Protein kinases) have
very important roles in PCD. The MAP kinase pathway
consists of 3 major parallel pathways designated as the
ERK (p42/44, Extracellular signal-Regulated Kinase),
SAPK/JNK (p46, Stress-Activated Protein Kinase/ c-Jun
NH2-terminal Kinase) and p38 pathways [12–14]. Acti-
vation of each pathway above involves phosphorylation
of a number of upstream and downstream family mem-
bers of the pathway. During growth factor deprivation
induced PCD in neuronal PC12 cells, there is a sustained
activation of the JNK and p38 pathways while the activi-
ties of ERK pathway is inhibited. It was proposed that a
dynamic balance of JNK-p38 and ERK can determine if
the neuronal cell will live or die [15]. Similar interplay of
the MAP kinases was shown in the PCD of non-neuronal
cells [16]. It is known that oxidized LDL can cause activa-
tion of MAP kinases [17,18]. Whether cholesterol oxides,
the main toxic components in oxidized LDL, can induce
MAP kinase activation, and whether MAP kinase activa-
tion has a role in cholesterol oxide induced PCD remain
to be investigated, and is the subject of this study.
Peroxisome proliferator-activated receptors (PPARs) be-
long to a group of nuclear receptors which includes ster-
oid, retinoid, thyroid hormone receptors and others [19–
21]. There are three types of PPARs: PPARα  is found pre-
dominantly in the liver, heart, kidney, brown adipose
and stomach mucosa, and is important for lipid catabo-
lism. PPARγ  is found in adipose tissues, and is important
for adipogenesis. PPARβ  is found in most tissues, but its
role is less well-defined.
PPARγ  is expressed in atherosclerotic lesions [22] and is
important in the process of atherogenesis. Depending on
the experimental system and the particular question
asked, PPARγ  can be involved with pro-atherogenesis or
anti-atherogenesis. For example, PPARγ  is involved in a
positive feedback mechanism that induces the formation
of foam cells [23]. On the other hand, activation of
PPARγ  was shown to inhibit monocyte [24] and macro-
phage [25] inflammatory responses by preventing the ac-
tivation of nuclear transcription factors, such as NF-kB
(nuclear factor-kappa B), AP-1 (activator protein-1) and
STAT 1 (signal transducer and activator of transcription
1). Since inflammation plays an important role in athero-
genesis, this anti-inflammatory effect of PPARγ  should
help to reduce the risk of atherogenesis. Development of
PPAR agonists that retain the antiatherogenic activity
but dismiss the proatherogenic activities will be of great
value [26].
Many naturally occurring or synthetic compounds are
agonists for the PPARs [20,21]. For example, a number
of prostaglandins are agonists for PPARγ  . The prostag-
landin, 15-deoxy-delta 12, 14-PGJ2 (15d-PGJ2), is the
most potent endogenous PPARγ  agonist known. On the
other hand, many synthetic compounds such as the non-
steroid anti-inflammatory drugs (NSAIDs) are PPARα
and PPARγ  agonists [27]. Since these are agents used
clinically for other purposes, it is important to determine
whether interaction of these agents with PPARs could
modulate atherogenesis in a positive or negative man-
ner.
While most research regarding cholesterol oxides are fo-
cused on the cardiovascular system, it should be noted
that the nervous tissue has the ability to generate choles-
terol oxides, which may exert toxic effect on cells and tis-
sues of the nervous system. For example, it has been
shown that synaptosomes and mitochondria prepared
from CNS tissue can convert cholesterol to cholesterol
oxides, which may play an important role in brain tissue
damage during oxidative stress [28]. Consistent with this
notion, we have shown cholesterol oxides are toxic to
neuronal PC12 cells [29,30] and neurons derived from
sympathetic ganglia [31], retina [32] and cerebellum
[33].
Microglia in the central nervous system express scaven-
ger receptors and are involved in the oxidized LDL up-
take and metabolism [34]. These cells are, thus, the
macrophage-equivalent in the central nervous system
[35]. Results from this laboratory showed that cholester-
ol oxides can cause programmed cell death in microglia
[7], which suggests that microglia, similar to macrophag-
es, can be a potential target for oxidized LDL toxicity.BMC Pharmacology 2001, 1:10 http://www.biomedcentral.com/1471-2210/1/10
Based on the observations that: 1. cholesterol oxides
cause PCD but the involvement of MAP kinases remains
to be investigated; 2. PPARs are important in atheroscle-
rosis but the effect of PPAR activation on cholesterol ox-
ide induced PCD has not been determined, this study
was designed to test if a dysregulation of MAP kinases
was associated with the cholesterol oxide induced PCD,
and to determine if PPAR activation could modulate the
cholesterol oxide induced PCD.
Results
Cytotoxicity of 25-OH-cholesterol toward microglia
A set of dose- and time-response experiments indicated
that 5, 10 and 20 µM 25-OH-cholesterol treatment for
one day reduced the viability to ~97, 70 and 52% of con-
trols, respectively (Fig. 1). This agent at 5 µM reduced the
viability to ~9% of controls after a 2-day treatment. In
contrast, 7-β -OH-cholesterol was much less toxic to mi-
croglia, such that this agent at 20 µM showed little toxic-
ity to the cells after a 1-day treatment (Fig. 2). A 3-day
treatment of the cells with 20 µM 7-β -OH-cholesterol re-
duced the viability to ~81% of controls. These results
confirmed and extended those obtained from our previ-
ous study [7].
Activation of c-jun as a result of 25-OH-cholesterol treat-
ment
Because c-jun was shown to play important roles in pro-
grammed cell death in many cell types [20,21], and mi-
croglia were shown to undergo programmed cell death
after cholesterol oxide treatment [7], experiments were
performed to determine if c-jun activation was involved
in cholesterol oxide induced microglial cell death. Cells
were treated with 10 µM 25-OH-cholesterol or 7-β -OH-
cholesterol for 12 hours, then processed for Western blot
analyses. Antibodies against c-jun, phospho-c-jun (at
position serine 63) or ERK 1/2 (an antibody which can
recognize both ERK 1 and ERK 2) were used in this set of
experiments. Results indicated that both cholesterol ox-
ides caused an increase in c-jun in microglia, with 25-
OH-cholesterol showing a more pronounced increase
(Fig. 3). Furthermore, 25-OH-cholesterol caused the
phosphorylation of c-jun, a phenomenon not observed in
7-β -OH-cholesterol treated microglia. The levels of ERK
1/2 were not altered by either treatment. These results
suggested that c-jun activation was associated with the
toxicity of cholesterol oxides.
A set of experiments was performed to determine any
dose-dependent change in c-jun activation by 25-OH-
cholesterol. Microglia were treated with 0, 1.25, 2.5, 5, 10
or 20 µM 25-OH-cholesterol for 12 hours, then proc-
essed for Western blot analysis. Results indicated that
25-OH-cholesterol treatment led to an increase in c-jun
and phospho-c-jun at serine 63. The levels of ERK 1/2
were not altered by this treatment (Fig. 4).
Time-dependent change of MAP kinase activities
Further studies were performed to determine the effect
of 25-OH-cholesterol on different members of MAP ki-
nases. The time-dependent change in c-jun, ERK and
p38 levels was determined. Cells were treated with 10
µM 25-OH-cholesterol for 1, 3, 6, 12 or 24 hours, then
processed for Western blot analyses. Results indicated
that there was an increase in c-jun after 25-OH-choles-
terol treatment between 1–12 hours of treatment. This
protein dropped to a non-detectable level at 24 hours af-
ter treatment. In addition, there was an increase in the
levels of phospho-c-jun on the serine residues (at both
position 63 and position 73). The levels of JNK (JNK 1
and JNK 2), however, were not altered (Fig. 5).
The levels of ERK1/2 were similar during the first 6
hours, then dropped between 12–24 hours after treat-
ment. The levels of phospho-ERK increased between 1–
6 hours after treatment, then decreased to a non-detect-
able level afterwards (Fig. 5). This decrease in phospho-
ERK expression occurred at a time coincided with the ap-
pearance of phospho-c-jun. The changes in p38 or phos-
pho-p38 levels were minimal (Fig. 5).
Modulation of c-jun activation by PPAR agonists
It was reported that PPAR activation could down-regu-
late the activity of AP-1 by interfering with the functions
of c-jun [36,37]. Therefore, the following set of experi-
ments was designed to test if PPAR activation could re-
duce c-jun activation in 25-OH-cholesterol treated
Figure 1
Effect of 25-OH-cholesterol on cell viability. Microglia were
treated with various concentrations of 25-OH-cholesterol
for 1 or 2 days, then the viability of each treatment was
determined.
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microglia. PPAR agonists including the prostaglandin,
15d-PGJ2, and two non-steroid anti-inflammatory
drugs, indomethacin and ibuprofen, were tested in this
series of experiments. Cells were treated with 5 µM 25-
OH-cholesterol together with these PPAR agonists for 12
hours, then processed for Western blot analyses. Anti-
bodies against c-jun, phospho-c-jun (at serine 63) and
ERK 1/2 were used in this set of experiments. Results in-
dicated that while 25-OH-cholesterol induced the ex-
pression of c-jun and phospho-c-jun, these PPAR
agonists reduced the expression to various degrees. The
apparent potency to reduce phospho-c-jun among the
three agents tested was: 15d-PGJ2 > indomethacin > ibu-
profen (Fig. 6). These results indicated that while 15d-
PGJ2 was very effective in inhibiting c-jun activation,
ibuprofen appeared to be ineffective in this regard.
PPAR agonists attenuate cholesterol oxide induced cyto-
toxicity in microglia
Since PPAR agonists appeared to reduce the c-jun activa-
tion caused by 25-OH-cholesterol treatment, the follow-
ing experiment was designed to test if these agents could
reduce 25-OH-cholesterol induced cytotoxicity. Cells
were treated with 5 µM 25-OH-cholesterol together with
PPAR agonists to be tested for 2 days, then the viability
of each treatment was determined. Results indicated that
15d-PGJ2 could prevent 25-OH-cholesterol induced cell
death in a dose-dependent manner. While treatment of
the cells with 5 µM 25-OH-cholesterol reduced the cell
viability to ~7% of controls, addition of 0.62, 1.25, 2.5, 5
or 10 µM 15d-PGJ2 raised the viabilities to ~10, 14, 18, 34
or 48%, respectively (Fig. 7). The rescue by 5 µM and 10
µM 15d-PGJ2 was statistically significant (p < 0.001).
This agent at concentrations above 10 µM was toxic to
microglia. The solvent for 15d-PGJ2, methylacetate, was
without any rescue effect.
Indomethacin also prevented 25-OH-cholesterol in-
duced cell death in a dose-dependent manner (Fig. 8).
This agent at 12.5, 25, 50, or 100 µM raised the viability
from ~8% to ~11, 13, 19 or 31% of controls, respectively.
A further increase in indomethacin to 200 µM did not in-
crease cell viability. The rescue by 50–200 µM in-
domethacin was statistically significant (p < 0.001).
Ibuprofen, on the other hand, had little rescue effect
even at 200 µM (Fig. 9). It is important to note that this
agent also had no inhibitory effect on c-jun activation
(Fig. 6).
While 15d-PGJ2 is considered to be a PPARγ  agonist, in-
domethacin and ibuprofen can activate both PPARγ  and
PPARα  [27]. The following experiment was conducted to
determine if a pure PPARα  agonist, WY14643, could
modulate the 25-OH-cholesterol induced cytotoxicity.
Results indicated that this agent was without rescue ef-
fect at 25, 50 or 100 µM. At 200 µM, WY14643 raised the
viability from ~10% to ~28% of controls. The difference
Figure 2
Effect of 7-β -OH-cholesterol on cell viability. Microglia were
treated with various concentrations of 7-β -OH-cholesterol
for 1, 2 or 3 days, then the viability of each treatment was
determined. Results from Fig. 1 and Fig. 2 indicated that 25-
OH-cholesterol was more toxic to these cells as compared
with 7-β -OH-cholesterol.
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Figure 3
Activation of c-jun by 25-OH-cholesterol. Cells were treated
with 10 µM 25-OH-cholesterol or 10 µM 7-β -OH-choles-
terol for 12 hours, then processed for Western blot analy-
ses. Antibodies against c-jun, phospho-c-jun (at serine 63)
and ERK 1/2 were used in this set of experiments. Concur-
rent electrophoresis procedures were performed for each
antibody. Results indicated that c-jun activation, i.e., phos-
phorylation of c-jun, was associated with the toxicity of 25-
OH-cholesterol.
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was statistically significant (p < 0.001). No further in-
crease in viability could be achieved by this agent (Fig.
10).
Since 25-OH-cholesterol induced an alteration of phos-
pho-ERK 1/2 during the first 6 hours of treatment (Fig.
5), an experiment was performed to test if inhibition of
ERK pathways could affect 25-OH-cholesterol induced
cell death. Microglia were treated with 5 µM 25-OH-cho-
lesterol together with 10 µM AG126 (ERK inhibitor),
PD98059 (MEK inhibitor, an up-stream member in the
ERK pathway) for 2 days, then the viability of each treat-
ment was determined. Results indicated that neither of
the pharmacological agents tested had any rescue effect
toward 25-OH-cholesterol induced cytotoxicity. Similar-
ly, the p38 pathway inhibitor, SB203580, had no rescue
effect under the same experimental conditions (results
not shown).
Discussion
Cholesterol oxides are formed in cholesterol-containing
food (powdered milk, cheese, egg products) during stor-
age [38,39] or during cholesterol catabolism in animals
[40]. The level of cholesterol oxide in meat product in-
creases significantly during the cooking process [39].
Animals can take up cholesterol oxides in a way similar
to the absorption of cholesterol. Cholesterol oxides given
exogenously can be cleared from plasma rapidly and be
widely redistributed in different parts of the body [41].
Cholesterol oxides and authentic cholesterol are trans-
ported within the cell by a similar mechanism, but the
transport is more efficient for cholesterol oxides [42].
High levels of cholesterol oxides have been observed in
hypercholesterolemic animals. For example, the plasma
level of 7-OH-cholesterol increases from 15 µM to ap-
proximately 200 µM in rabbits fed with high cholesterol
diet for 6 weeks [43].
Cholesterol oxide treatment can lead to alterations of cel-
lular functions. These compounds can activate some nu-
clear receptors including steroidogenic factor 1 [44] and
LXR, which may be partially responsible for their biolog-
ical activities [45,46]. Cholesterol oxides are inhibitors of
HMG-CoA reductase, the key enzyme of cholesterol bio-
synthesis pathway [47]. The ability to bind to an intrac-
ellular receptor, oxysterol binding protein, may be
responsible for their inhibition of cholesterol biosynthe-
sis [48,49]. It should be noted that addition of cholester-
ol does not prevent cholesterol oxide induced cell death,
which leads to the suggestion that inhibition of choles-
terol synthesis is not the cause of cholesterol oxide in-
duced PCD [50,51]. The critical events that result in
cholesterol oxide induced cytotoxicity remain to be de-
termined.
Results from this study indicated that 25-OH-cholesterol
was very cytotoxic to microglia, such that a 2-day treat-
Figure 4
Dose-dependent effect of 25-OH-cholesterol on c-jun activa-
tion. Cells were treated with 0. 1.25, 2.5, 5, 10 or 20 µM 25-
OH-cholesterol for 12 hours, then processed for Western
blot analyses. Antibodies against c-jun, phospho-c-jun (at ser-
ine 63) and ERK 1/2 were used in this set of experiments.
Concurrent electrophoresis procedures were performed for
each antibody. Results indicated that 25-OH-cholesterol
caused a dose-dependent increase in c-jun activation.
Figure 5
Time-dependent alterations of MAP kinases activity. Cells
were treated with 10 µM 25-OH-cholesterol for 0, 1, 3, 6, 12
or 24 hours, then processed for Western blot analysis. Anti-
bodies against c-jun, phospho-c-jun (serine 63 or serine 73),
JNK, ERK 1/2, phospho-ERK, p38 and phospho-p38 were
used in this series of experiments. See text for an analysis of
the results.BMC Pharmacology 2001, 1:10 http://www.biomedcentral.com/1471-2210/1/10
ment with 5 µM 25-OH-cholesterol reduced cell viability
to 5–10% of controls. In contrast, 7-β -OH-cholesterol
was much less toxic to microglia (Fig. 1,2). Selective tox-
icity of cholesterol oxides toward a particular cell type
was also observed in our previous studies [29,31–33].
Further experiments with Western blot analyses indicat-
ed that the cytotoxicity of cholesterol oxides was associ-
ated with their abilities to cause c-jun activation, as
evidenced by the increase in activated c-jun, i.e., phos-
pho-c-jun, in 25-OH-cholesterol treated cells but not in
7-β -OH-cholesterol treated cells (Fig. 3). There was a
dose-dependent increase in c-jun activation in cells
treated with 25-OH-cholesterol (Fig. 4).
It has been suggested that a dysregulation of MAP kinas-
es is responsible for the growth factor deprivation [15] or
chemotherapeutic agent [16] induced PCD. Consistent
with this idea, results from this study suggest that an un-
favorable balance of the JNK and ERK causes the cell
death observed in cholesterol oxide treated microglia.
Cells treated with 25-OH-cholesterol showed a time-de-
pendent increase in c-jun protein as well as phospho-c-
jun (Fig. 5). This c-jun activation was apparent at 6 hours
after treatment. In contrast, 25-OH-cholesterol caused a
slight, initial increase in phospho-ERK, which decreased
to a non-detectable level 6 hours after treatment. The
change in p38 and phospho-p38, on the other hand, was
not as apparent. It was reported that rabbits fed with
high-cholesterol diet exhibited high JNK protein levels
and JNK activity in their atherosclerotic lesions, and ox-
idized LDL caused JNK activation in cultured smooth
muscle cells [18]. Based on this study, there is a possibil-
ity that cholesterol oxides in oxidized LDL were respon-
sible for those previous observations.
Activation of the JNK pathway can lead to the phospho-
rylation of downstream members including c-jun that
belongs to the AP-1 transcription factor family [12,52].
Because results from this study indicated that JNK path-
way was activated by 25-OH-cholesterol, one could ex-
pect that AP-1 would be activated in cells treated with
cholesterol oxides. Consistent with this idea, it was
shown that LDL could induce AP-1 activity in endothelial
cells [53] and cholesterol oxide treatment could lead to
increased AP-1 DNA binding activity and AP-1 depend-
ent transcription in other cell types [54,55]. Results from
this study, thus, complemented and extended the find-
ings of those reports.
The PPARγ  agonist, 15d-PGJ2, functions as a general in-
hibitor of microglial functions [56–58]. For example,
this agent inhibits the expression of inducible nitric ox-
ide synthase, tumor necrosis factor-α , interleukin-1 β
and major histocompatibility complex class II in activat-
ed microglia. Inhibition of the signal transducer and ac-
tivator of transcription 1 (STAT-1) and the nuclear factor
kB (NF-kB) may be partially responsible for the inhibito-
ry effects. Results from this study further indicated that
PPAR agonists could reduce c-jun activation (Fig. 6).
Given the suggestion that an up-regulation of c-jun is a
Figure 6
PPAR agonists reduced c-jun activation in 25-OH-cholesterol
treated microglia. Cells were treated with 5 µM 25-OH-cho-
lesterol together with 10 µM 15d-PGJ2, 100 µM indometh-
acin or 100 µM ibuprofen for 12 hours, then processed for
Western blot analyses. Antibodies against c-jun, phospho-c-
jun (at serine 63) and ERK 1/2 were used in this set of exper-
iments. Results indicated that these agents reduced 25-OH-
cholesterol induced c-jun activation to various degrees.
Figure 7
Effect of 15d-PGJ2 on 25-OH-cholesterol induced cell death.
Cells were treated with 5 µM 25-OH-cholesterol plus vari-
ous concentrations of 15d-PGJ2 for 2 days, then the viability
of each treatment was determined. *P< 0.001BMC Pharmacology 2001, 1:10 http://www.biomedcentral.com/1471-2210/1/10
cause of PCD [15,16], a reduction in c-jun activation by
PPAR agonists should attenuate 25-OH-cholesterol in-
duced cytotoxicity. Consistent with this idea, results
from this study indicated that 15d-PGJ2, indomethacin
and WY14643 could attenuate the cytotoxicity caused by
25-OH-cholesterol to various degrees (Fig. 7,8,10). Since
the protective effect of WY14643 could be observed only
at concentrations higher than 200 µM, there is a possi-
bility that this agent acted on the PPARγ  receptor to
achieve the protection. Similar protective roles of PPAR
agonists have been shown in other nervous tissues. For
example, PPARγ  agonists were shown to protect cy-
tokine-induced PCD in cerebellar granule cells [59].
These agents could also block the neurotoxic effects
caused by β -amyloid activated microglia, and thus might
be beneficial in the treatment of Alzheimer's disease
[60]. In non-neuronal tissues, PPARα  activation was
shown to suppress both spontaneous rat hepatocyte PCD
and the PCD induced by transforming growth factor-β 1
[61].
Conclusions
Treatment of microglia with 25-OH-cholesterol caused
an induction of c-jun, phospho-c-jun and a reduction in
cellular viability. PPAR agonists reduced the 25-OH-cho-
lesterol induced c-jun activation and attenuated the cy-
totoxicity. This group of compounds may be useful in
future development of pharmacological agents against
cholesterol oxide induced cytotoxicity.
Materials and methods
Cell culture
The N9 murine microglia cell line was a gift kindly pro-
vided by Dr. P. Ricciardi-Castagnoli [62]. This cell line
has been used extensively as a model for microglia [63–
65]. These cells were derived by immortalization of day
13 embryonic brain cultures with a retrovirus carrying an
activated v-myc oncogene. The cultures were maintained
in Minimum Essential Medium (MEM, GibcoBRL,
Grand Island, NY) supplemented with 10% heat-inacti-
vated fetal bovine serum (Sigma, St. Louis, MO), 1.4 mM
glutamine (GibcoBRL, Grand Island, NY) and 20 µM 2-
mercaptoethanol (Sigma, St. Louis, MO). WY14643 and
15d-PGJ2 were purchased from Cayman (Ann Arbor,
MI). Indomethacin, ibuprofen and all other pharmaco-
logical and general biochemical reagents were purchased
from Sigma (St. Louis, MO) unless otherwise stated.
Cell viability
Cells grown in 96-well plates (20,000 cells/well, ~90%
confluency) were treated with testing agents for a period
of time as indicated in the figure legends; then, the via-
bility from each treatment was determined by the MTT
(3-(4,5-dimethylthiazole-2yl)-2,5-diphenyltetrazolium
bromide) assay [66]. Culture medium was removed after
treatment, then 100 µl MTT solution (100 µg/ml pre-
pared in MEM) was added to each well. The cultures
were incubated at 37°C for one hour in a tissue culture
incubator. The MTT solution was then removed, and the
cells in each well were lysed by the addition of 100 µl
dimethly sulfoxide. The plate was placed on a shaker for
one hour at room temperature to complete the lysing
Figure 8
Effect of indomethacin on 25-OH-cholesterol induced cell
death. Cells were treated with 5 µM 25-OH-cholesterol plus
various concentrations of indomethacin for 2 days, then the
viability of each treatment was determined. *P < 0.001
Figure 9
Effect of ibuprofen on 25-OH-cholesterol induced cell death.
Cells were treated with 5 µM 25-OH-cholesterol plus vari-
ous concentrations of ibuprofen for 2 days, then the viability
of each treatment was determined.BMC Pharmacology 2001, 1:10 http://www.biomedcentral.com/1471-2210/1/10
process, then the optical density of each well was meas-
ured by a 96-well plate reader with a filter setting at 570
nm (reference filter setting was 630 nm).
Western blot analysis
Protein isolated from cytoplasm was separated by SDS-
PAGE on 10% polyacrylamide gels and transferred to ni-
trocellulose membranes (NitroBind, MSI, Westborough,
MA), then incubated with primary antibody overnight at
4°C. Specific bands were detected by incubating the
membrane with horseradish peroxidase conjugated sec-
ondary antibody for 45 minutes at room temperature,
then with ECL Western Blotting Detection Reagents
(Amersham Life Science, Arlington Heights, IL) accord-
ing to the manufacturer's protocol. The primary antibod-
ies used in this set of experiments were from New
England Biological (anti-phospho-c-jun at serine 73,
used at 1:1000) or Santa Cruz (anti-c-jun, used at
1:3000; anti-phospho-c-jun at serine 63, used at 1:1000,
anti-JNK, used at 1:3000; anti-ERK 1/2, used at 1:3000;
anti-phospho-ERK, used at 1:2000; anti-p38, used at
1:3000; anti-phospho-p38, used at 1:1000).
Statistical analysis
Unless otherwise stated, results of cell viability experi-
ments were pooled from 12 replicate samples derived
from 3 independent experiments, and expressed as mean
± SEM. Statistical analysis was performed by analysis of
variance (one-way ANOVA) followed by the Bonferroni
test to determine the significance of difference.
List of abbreviations
15d-PGJ2, 15-deoxy-delta 12, 14-PGJ2; AP-1, activator
protein-1; ERK, p42/44, Extracellular signal-Regulated
Kinase; LDL, low density lipoprotein; MAP kinases, Mi-
togen-Activated Protein kinases; MTT (3-(4,5-dimethyl-
thiazole-2yl)-2,5-diphenyltetrazolium bromide); PCD,
programmed cell death; PPARs, peroxisome prolifera-
tor-activated receptors; SAPK/JNK, Stress-Activated
Protein Kinase/ c-Jun NH2-terminal Kinase.
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